Sign in or create an account to add this stock to your watchlist.
About Strongbridge Biopharma (NASDAQ:SBBP)
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that is used for treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200
Debt
Debt-to-Equity Ratio41.16
Current Ratio8.90
Quick Ratio8.74
Price-To-Earnings
Trailing P/E Ratio-5.21
Forward P/E Ratio-3.89
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.05 million
Price / Sales48.76
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book188.75
Profitability
EPS (Most Recent Fiscal Year)($1.45)
Net Income$-113,480,000.00
Net Margins-1,032.62%
Return on Equity-1,224.30%
Return on Assets-59.45%
Miscellaneous
Employees66
Outstanding Shares45,530,000
Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions
What is Strongbridge Biopharma's stock symbol?
Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."
How were Strongbridge Biopharma's earnings last quarter?
Strongbridge Biopharma (NASDAQ:SBBP) released its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.25. The biotechnology company had revenue of $3.87 million for the quarter, compared to the consensus estimate of $3.25 million. Strongbridge Biopharma had a negative net margin of 1,032.62% and a negative return on equity of 1,224.30%. View Strongbridge Biopharma's Earnings History.
When is Strongbridge Biopharma's next earnings date?
What price target have analysts set for SBBP?
3 Wall Street analysts have issued 12 month price targets for Strongbridge Biopharma's shares. Their forecasts range from $12.00 to $18.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $14.6667 in the next year. View Analyst Ratings for Strongbridge Biopharma.
What are Wall Street analysts saying about Strongbridge Biopharma stock?
Here are some recent quotes from research analysts about Strongbridge Biopharma stock:
- 1. According to Zacks Investment Research, "Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing's syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. " (5/12/2018)
- 2. HC Wainwright analysts commented, "BioLife reported 1Q18 biopreservation media revenue of $3.8, up 22% sequentially and 61% y/y. Margin also continue to rise with increasing volume, coming in at 64% in 1Q. The company is cash flow positive and currently has $9.6M in cash on the balance sheet (including $2.6M from warrants exercised recently). Biolife’s valuation continues to rise as media revenue grows and the company becomes more deeply integrated into an evolving cell therapy space. We are increasing our outyear estimates for cell media revenue which increases our 12-month price target to $12, from $9.." (5/11/2018)
- 3. Cantor Fitzgerald analysts commented, "Added Focus on RECORLEV into Mid-2108. Ahead of the mid-2018 SONICS top-line readout, we anticipate greater attention to shift towards the RECORLEV opportunity in Cushing’s syndrome. As a reminder, we believe Recorlev has demonstrated greater control over cortisol secretion over ketoconazole with fewer liabilities associated with liver enzyme elevations. Strongbridge plans to host an investor and analyst day on April 5, 2018, to discuss these opportunities and development progress. Following SONICS we anticipate data from LOGICS in 1Q19, a slight slippage from 4Q18, previously." (3/12/2018)
Who are some of Strongbridge Biopharma's key competitors?
Some companies that are related to Strongbridge Biopharma include Amneal Pharmaceuticals (AMRX), TherapeuticsMD (TXMD), Radius Health (RDUS), Uniqure (QURE), Epizyme (EPZM), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), Immuron (IMRN), Intra-Cellular Therapies (ITCI), Retrophin (RTRX), Mirati Therapeutics (MRTX), Apellis Pharmaceuticals (APLS), Revance Therapeutics (RVNC), Zai Lab (ZLAB) and Alder BioPharmaceuticals (ALDR).
Who are Strongbridge Biopharma's key executives?
Strongbridge Biopharma's management team includes the folowing people:
- Mr. Matthew Pauls, CEO, Pres & Director (Age 47)
- Mr. A. Brian Davis, Chief Financial Officer (Age 51)
- Dr. Fredric Cohen, Chief Medical Officer (Age 53)
- Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
- Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations
Has Strongbridge Biopharma been receiving favorable news coverage?
Press coverage about SBBP stock has trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Strongbridge Biopharma earned a coverage optimism score of 0.05 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Strongbridge Biopharma's major shareholders?
Strongbridge Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Caxton Corp (11.81%), Lyon Street Capital LLC (6.99%), BlackRock Inc. (3.94%), Opaleye Management Inc. (3.49%), Harvest Capital Strategies LLC (1.81%) and Park West Asset Management LLC (1.72%). View Institutional Ownership Trends for Strongbridge Biopharma.
Which major investors are selling Strongbridge Biopharma stock?
Which major investors are buying Strongbridge Biopharma stock?
SBBP stock was acquired by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Harvest Capital Strategies LLC, Park West Asset Management LLC, BlackRock Inc., Opaleye Management Inc., Millennium Management LLC, Wells Fargo & Company MN and Spark Investment Management LLC. View Insider Buying and Selling for Strongbridge Biopharma.
How do I buy shares of Strongbridge Biopharma?
Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Strongbridge Biopharma's stock price today?
One share of SBBP stock can currently be purchased for approximately $7.55.
How big of a company is Strongbridge Biopharma?
Strongbridge Biopharma has a market capitalization of $332.40 million and generates $7.05 million in revenue each year. The biotechnology company earns $-113,480,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Strongbridge Biopharma employs 66 workers across the globe.
How can I contact Strongbridge Biopharma?
Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]
MarketBeat Community Rating for Strongbridge Biopharma (SBBP)
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Strongbridge Biopharma (NASDAQ:SBBP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Strongbridge Biopharma in the last 12 months. Their average twelve-month price target is $14.6667, suggesting that the stock has a possible upside of 94.26%. The high price target for SBBP is $18.00 and the low price target for SBBP is $12.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $14.6667 | $14.6667 | $14.6667 | $13.3333 |
| Price Target Upside: | 94.26% upside | 76.71% upside | 86.84% upside | 131.88% upside |
Strongbridge Biopharma (NASDAQ:SBBP) Consensus Price Target History
Strongbridge Biopharma (NASDAQ:SBBP) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Strongbridge Biopharma (NASDAQ:SBBP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Strongbridge Biopharma (NASDAQ SBBP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.20%
Institutional Ownership Percentage: 67.69%
Strongbridge Biopharma (NASDAQ SBBP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Strongbridge Biopharma (NASDAQ SBBP) News Headlines
| Source: |
|
Strongbridge Biopharma (NASDAQ:SBBP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Strongbridge Biopharma (NASDAQ:SBBP) Income Statement, Balance Sheet and Cash Flow Statement
Strongbridge Biopharma (NASDAQ SBBP) Stock Chart for Saturday, May, 26, 2018
Loading chart…
